Efficacy

Efficacy of Perjeta (Pertuzumab) in Breast Cancer

Perjeta (pertuzumab) is a monoclonal antibody designed to target the HER2 receptor, a protein that is overexpressed in some types of breast cancer. Pertuzumab works by binding to the HER2 receptor and preventing the pairing (dimerization) of HER2 with other HER receptors, which is a process that can promote the growth of cancer cells. When used in combination with trastuzumab and chemotherapy, Perjeta has been shown to significantly improve progression-free survival (PFS) and overall survival (OS) in patients with HER2-positive metastatic breast cancer. The combination therapy is particularly effective in the first-line treatment setting and has become a standard of care for patients with this aggressive form of breast cancer.

In the adjuvant setting, for patients with HER2-positive early breast cancer, Perjeta added to trastuzumab and chemotherapy has demonstrated an improvement in invasive disease-free survival (iDFS) compared to trastuzumab and chemotherapy alone. The addition of Perjeta to standard therapy has been shown to reduce the risk of breast cancer recurrence and death, thereby offering a significant benefit to patients with early-stage HER2-positive breast cancer.

Efficacy of Truqap (capivasertib) in Breast Cancer

Truqap (capivasertib) is an investigational small molecule inhibitor of the AKT pathway, which is involved in cell growth, proliferation, and survival. While capivasertib is not yet approved for clinical use, it has been studied in clinical trials for its potential efficacy in treating various cancers, including breast cancer. In breast cancer, the AKT pathway can be hyperactivated, leading to tumor growth and resistance to other cancer therapies. Capivasertib has been evaluated in combination with other cancer treatments, such as fulvestrant or paclitaxel, to assess its efficacy in patients with advanced or metastatic breast cancer.

Early clinical trials have suggested that capivasertib, when used in combination with other therapies, may improve outcomes in patients with breast cancer, particularly in those with AKT pathway alterations. These studies have indicated that the addition of capivasertib to standard treatments could potentially enhance antitumor activity and may lead to improved progression-free survival in certain subgroups of breast cancer patients. However, as an investigational drug, capivasertib is still undergoing clinical trials to establish its safety and efficacy profile, and more data are needed to confirm its role in the treatment of breast cancer.